Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) моноклональный антитело, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.